MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/ijms26115269

Медицинская библиотека · International journal of molecular sciences · 2025

Feasibility Assessment of Autologous Human Immune System (HIS) ImmunoGraft Platform Development Using Autologous Mobilized Peripheral Blood (MPB) CD34 Cells Derived from Adult HNSCC Patient.

Verma Bhavna, Chen Georgia Zhuo, Waller Edmund K, Patel Mihir, Anderson Allyson, Goodwin Neal, Wesa Amy, Teng Yong, Saba Nabil F

СтатьяПеревод пока не подготовлен

Аннотация

Humanized mice generated by hematopoietic stem cell (HSC) transplantation are limited by the immune system developed being allogeneic to the tumor. We have innovated a platform to reconstitute an autologous human immune system (HIS) in immunodeficient NOG-EXL mice from mobilized peripheral blood (MPB)-CD34 cells, along with PDX generated from the same patient's tumor tissue. Patients consented under an IRB-approved protocol for tumor biopsy and HSC apheresis at Emory University. HSC collection included mobilization with G-CSF and plerixafor, immunomagnetic bead isolation with CliniMACS, and cryopreservation of CD34+ cells. PDX were established from biopsies or surgical specimens by passaging into immunodeficient mice. Irradiated NOG-EXL mice were engrafted with HSCs by intravenous transplantation of CD34+ HSC. Engraftment of human T cells, B cells, and myeloid cells in peripheral blood was assessed by serial flow cytometry of blood samples, with final assessment of immune components in spleen and bone marrow at 30 weeks. Twenty-eight PDX models were generated from 43 patients with HNSCC; 1 patient underwent apheresis. HSC engraftment in blood was observed in 100% of NOG-EXL mice at 8 weeks post-transplant, with 5-20% hCD45+ cells present in the periphery. B-cell development was predominant at early time points and declined over time. Human T-cell and subset development of CD4+ and CD8+ T cells were observed in blood from 15 weeks post-transplant. Strong development of the myeloid lineage (CD33+) was observed starting at 8 weeks and persisted throughout the study. These data demonstrate that mobilization and apheresis of HNSCC patients is technically and clinically feasible and may allow the establishment of autologous HIS-PDX mice.

Для цитирования: Verma Bhavna, Chen Georgia Zhuo, Waller Edmund K, Patel Mihir, Anderson Allyson, Goodwin Neal, Wesa Amy, Teng Yong, Saba Nabil F. Feasibility Assessment of Autologous Human Immune System (HIS) ImmunoGraft Platform Development Using Autologous Mobilized Peripheral Blood (MPB) CD34 Cells Derived from Adult HNSCC Patient.. International journal of molecular sciences. 2025. DOI: 10.3390/ijms26115269.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.